pimodivir

non‐nucleotide inhibitor of the polymerase basic protein 2 (PB2) subunit of the influenza A that is active against H1N1, H7N9 and H5N1, as well as influenza A strains with reduced susceptibility to NAIs

Also Known As:

(2S,3S)-3-((5-Fluoro-2-(5-fluoro-1H-pyrrolo(2,3-b)pyridin-3-yl)-4-pyrimidinyl)amino)bicyclo(2.2.2)octane-2-carboxylic acid; Bicyclo(2.2.2)octane-2-carboxylic acid, 3-((5-fluoro-2-(5-fluoro-1H-pyrrolo(2,3-b)pyridin-3-yl)-4-pyrimidinyl)amino)-, (2S,3S)-; JNJ-63623872; VX-787

Networked: 16 relevant articles (2 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds

Experts

1.	Leopold, Lorant: 3 articles (12/2022 - 01/2018)
2.	Vingerhoets, Johan: 3 articles (12/2022 - 01/2018)
3.	Charifson, Paul S: 3 articles (02/2017 - 03/2015)
4.	Clark, Michael P: 3 articles (02/2017 - 03/2015)
5.	Ledeboer, Mark W: 3 articles (02/2017 - 03/2015)
6.	Leeman, Joshua R: 3 articles (02/2017 - 03/2015)
7.	Perola, Emanuele: 3 articles (02/2017 - 03/2015)
8.	Anderson, David: 2 articles (12/2022 - 01/2019)
9.	Kosoglou, Teddy: 2 articles (12/2022 - 01/2019)
10.	van Duijnhoven, Wilbert: 2 articles (12/2022 - 01/2019)

Related Diseases

1.	Human Influenza (Influenza) 01/01/2023 - "Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study." 02/15/2023 - "To expand the chemical space of the known influenza polymerase PB2 inhibitor-pimodivir (formerly VX-787) and improve its pharmacokinetic profile, two pimodivir analogs containing 2,3-dihydro-imidazopyridine fragment (comp. " 12/01/2022 - "There was a lower incidence of influenza-related complications in the pimodivir group (7.9%) versus placebo group (15.6%). " 12/01/2022 - "Time to influenza symptom resolution was numerically shorter with pimodivir (72.45 hours) than placebo (94.15 hours). " 02/14/2021 - "Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase."
2.	Infections 01/01/2018 - "Pimodivir has potential to not only reduce viral load but to have a clinical impact on patients as a novel treatment for influenza A virus infection. " 01/01/2023 - "Sequencing of baseline samples in 206 of 223 (92.4%) randomized study participants with confirmed influenza A infection identified no polymorphisms at any predefined PB2 positions of interest for pimodivir and no phenotypic reduced susceptibility to pimodivir was observed. " 01/01/2016 - "JNJ-63623872 (formally known as VX-787; referred to here as JNJ872) is an orally bioavailable compound, which is in phase II clinical trials for the treatment of influenza A virus (IAV) infections. " 12/01/2022 - "Hospitalized patients with influenza A infection were randomized 2:1 to receive pimodivir 600 mg plus oseltamivir 75 mg or placebo plus oseltamivir 75 mg twice daily for 7 days in this phase 2b study. " 12/01/2022 - "A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study."

Related Drugs and Biologics

1.	Oseltamivir (Tamiflu)
2.	Neuraminidase (Sialidase)
3.	Antiviral Agents (Antivirals)
4.	favipiravir
5.	nitazoxanide (NTZ)
6.	ziresovir
7.	baloxavir
8.	presatovir
9.	Monoclonal Antibodies
10.	VX (EDIM)

Related Therapies and Procedures

1.	Therapeutics